Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.3%
Mon, 7 Oct 10:33

Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.3%Image source: Kameleon007 /www.istockphoto.com

Suven Life Sciences share price has plunged 5% and is presently trading at Rs 135.0.

Meanwhile, the BSE HEALTHCARE index is at 43,427.9 (down 0.3%).

Among the top losers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (down 5.0%) and GSK Pharma (down 4.0%).

ASTRAZENECA PHARMA (up 7.8%) and Natco Pharma (up 3.8%) are among the top gainers today.

Over the last one year, Suven Life Sciences has moved up from Rs 73.1 to Rs 135.0, registering a gain of Rs 61.9 (up 84.6%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,427.9, registering a gain of 52.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 147.0%), SUVEN PHARMACEUTICALS (up 105.5%) and Glenmark Pharma (up 99.4%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,860.9 (up 0.2%).

The top gainers among the BSE Sensex today are ITC (up 1.6%) and ICICI Bank (up 1.4%). The most traded stocks in the BSE Sensex are Tata Steel and Bharti Airtel.

In the meantime, NSE Nifty is at 25,020.7 . ITC and ICICI Bank are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 81,860.9, registering a gain of 16,348.8 points (up 25.0%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit fell 16.4% YoY to Rs -280 million for the quarter ended June 2024, compared to a loss of Rs 241 million a year ago. Net sales declined 73.5% to Rs 10 million during the period as against Rs 38 million in April-June 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -27.0.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Plunges 5%; BSE HEALTHCARE Index Down 0.3%". Click here!